Key Points
- CFO David Doherty sold 14,574 shares on March 6 at an average price of $13.84 for about $201,704, reducing his holdings by 14.1% to 88,803 shares (SEC filing disclosed).
- Surgery Partners missed Q4 EPS estimates ($0.12 reported vs. $0.31 expected) despite revenue beating estimates ($885M vs. $866.5M), leaving the company with a negative net margin and mixed analyst outlooks.
- The board authorized a $200 million share repurchase (up to ~9.7% of shares) even as multiple insiders sold shares the week of Mar 5–6 and a shareholder fraud probe was opened, adding potential uncertainty for investors.
Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) insider William Trenton Webb sold 1,794 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $13.86, for a total transaction of $24,864.84. Following the completion of the sale, the insider directly owned 72,455 shares of the company's stock, valued at $1,004,226.30. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
William Trenton Webb also recently made the following trade(s):
- On Friday, March 6th, William Trenton Webb sold 272 shares of Surgery Partners stock. The stock was sold at an average price of $13.93, for a total value of $3,788.96.
Surgery Partners Trading Down 0.4%
NASDAQ SGRY opened at $13.30 on Tuesday. The business's fifty day moving average is $15.16 and its 200-day moving average is $18.00. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.87 and a quick ratio of 1.71. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a one year low of $12.25 and a one year high of $24.60.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts' expectations of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The business's quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the business posted $0.44 EPS. Equities research analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current year.
Surgery Partners declared that its board has approved a stock repurchase plan on Thursday, February 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 9.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its shares are undervalued.
Trending Headlines about Surgery Partners
Here are the key news stories impacting Surgery Partners this week:
- Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
- Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
- Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
- Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
- Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
- Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)
Institutional Investors Weigh In On Surgery Partners
Several hedge funds and other institutional investors have recently modified their holdings of SGRY. Jones Financial Companies Lllp boosted its position in shares of Surgery Partners by 313.1% in the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company's stock valued at $27,000 after acquiring an additional 930 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Surgery Partners by 45,640.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company's stock worth $49,000 after acquiring an additional 2,282 shares during the period. PNC Financial Services Group Inc. lifted its stake in Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company's stock worth $58,000 after purchasing an additional 1,519 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Surgery Partners in the 3rd quarter worth approximately $121,000. Finally, State of Alaska Department of Revenue bought a new position in Surgery Partners in the 3rd quarter valued at $151,000.
Wall Street Analyst Weigh In
SGRY has been the subject of several research reports. Mizuho cut their price target on Surgery Partners from $19.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, March 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Surgery Partners in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Surgery Partners in a report on Monday, December 29th. Benchmark reiterated a "buy" rating on shares of Surgery Partners in a research note on Tuesday, March 3rd. Finally, Barclays dropped their target price on Surgery Partners from $18.00 to $14.00 and set an "equal weight" rating on the stock in a research report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.45.
View Our Latest Research Report on SGRY
Surgery Partners Company Profile
(
Get Free Report)
Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.
Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
